106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2018 All rights reserved
Disclaimer
is pocket card is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket card does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
hematologic-malignancies-guidelines. Copyright © 2018 by American Society of Clinical Oncolog y.
All rights reserved.
ASCOBMAMM17123a
Abbreviations
BMA, bone-modifying agents; CRAB, hypercalcemia, renal dysfunction, anemia or bone
disease; CT, computed tomography; FDA, U.S. Food and Drug Administration; mg,
milligram(s); MRI, magnetic resonance imaging ; ONJ, osteonecrosis of the jaw; PET, positron
emission tomography; USD, United States dollars
Source
Anderson K, Ismaila N, Flynn PJ, Halabi S, Jagannath S, Ogaily MS, Omel J, Raje N, Roodman
GD, Yee GC, Kyle RA. Role of Bone-Modifying Agents in Multiple Myeloma: American
Society of Clinical Oncolog y Clinical Practice Guideline Update. J Clin Oncol. 2018 Jan 17.
doi: 10.1200/JCO.2017.76.6402
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets,
frequently asked questions, and other clinical tools and resources, is available at
www.asco.org/hematologic-malignancies-guidelines and www.asco.org/guidelineswiki
